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Background
TG4010 is an immunotherapy using an attenuated and
modified poxvirus (MVA) coding for MUC1 and inter-
leukin-2 to induce a cellular immune response against
MUC1 expressing tumors. Previous Phase 2 trials have
demonstrated the efficacy and safety of TG4010 in com-
bination with chemotherapy. In addition, level of Triple
Positive Activated Lymphocytes (TrPAL; CD16+, CD56
+, CD69+) was identified as a potential biomarker pre-
dictive of efficacy
Methods
TIME is a double blind, placebo-controlled Phase IIb/III
study. The Phase IIb part compared first-line che-
motherapy combined with TG4010 or placebo and
further assessed the predictive value of baseline level of
TrPAL. Eligibility criteria included previously untreated
stage IV NSCLC, MUC1+ tumor by immunohistochem-
istry, PS ≤1. TG4010 (108 pfu) or placebo was given SC
weekly for 6 weeks (w), then every 3w up to progression,
in combination with chemotherapy. Primary endpoint
was progression-free survival (PFS) and secondary end-
points were response rate (ORR), duration of response,
survival (OS), safety and subgroup analyses according to
histology and level of TrPAL. (NCT01383148).
Results
222 pts were randomized 1:1. In pts with normal TrPAL
the study met its primary endpoint with a probability
>95% that the PFS HR is < 1 in pts treated with
TG4010. Preplanned subgroup analyses were performed
using an optimal cut-off value for the level of TrPAL
defining 2 subpopulations (low and high TrPAL). In 147
patients with low TrPAL, PFS was significantly increased
in TG4010 arm (HR=0.66 [CI95% 0.46-0.94] p= 0.010)
as well as OS (HR=0.67 [CI95%0.46-0.98) p=0.018)
while there was no benefit in pts with high TrPAL.
Activity was even more important in patients with low
TrPAL and non-squamous tumor (n=127) with PFS HR
=0.59 (CI95% 0.40-0.87; p=0.003), and OS HR=0.59
(CI95% 0.39-0.91; p=0.007). In this subgroup, ORR was
39.3% vs 30.3% and duration of response 43.1 vs
18.1weeks in TG4010 and placebo arms, respectively.
TG4010 related adverse events were mainly low-grade
injection site reactions. The impact of PDL1 expression
by immunohistochemistry in the tumor of patients trea-
ted with TG4010 supports the activity of TG4010
whether the tumor is positive or negative for PDL1
expression.
Conclusions
These results provide further evidence of the efficacy of
TG4010 in combination with chemotherapy in NSCLC
and of the potential of TrPAL as a predictive biomarker.
Future development of TG4010 is being planned, both
in combination with chemotherapy (Phase 3 part of the
TIME trial) and in combination with immune check-
point inhibitors.
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